Endovascular Treatment of HCC
Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly...
Gespeichert in:
| Veröffentlicht in: | NeuroQuantology 2022-01, Vol.20 (16), p.2321 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 16 |
| container_start_page | 2321 |
| container_title | NeuroQuantology |
| container_volume | 20 |
| creator | Atito, Medhat A H Mostafa Ahmed Mamdouh Al-Sharqawy Hashem, Moustafa Ali Abdelrahman Ghwiel |
| description | Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly into the tumor, minimizing systemic effects. Aim and objectives: Aim of the study was to evaluate the response of TACE treatment after 1,6,12 and 24 months comparing EASL criteria and the most recent modified RECIST (mRECIST) criteria and to assess the efficacy and tolerability of DEB-TACE for the treatment of HCC. Conclusion: DEB-TACE is more effective than cTACE in early and intermediate-stage HCC with fewer complications but without statistically significant superiority |
| doi_str_mv | 10.48047/NQ.2022.20.16.NQ88233 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2816742922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2816742922</sourcerecordid><originalsourceid>FETCH-proquest_journals_28167429223</originalsourceid><addsrcrecordid>eNpjYJAzNNAzsTAwMdf3C9QzMjAyAhJ6hmZ6foEWFkbGxkwMnIbGBsa6poamBhwMXMXFWQYGpuYGlmacDLKueSn5ZYnFyaU5iUUKIUWpiSW5qXklCvlpCh7OzjwMrGmJOcWpvFCam0HZzTXE2UO3oCi_sDS1uCQ-K7-0KA8oFW9kYWhmbmJkaWRkTJwqAAP0MWk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2816742922</pqid></control><display><type>article</type><title>Endovascular Treatment of HCC</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Atito, Medhat A H ; Mostafa Ahmed Mamdouh Al-Sharqawy ; Hashem, Moustafa ; Ali Abdelrahman Ghwiel</creator><creatorcontrib>Atito, Medhat A H ; Mostafa Ahmed Mamdouh Al-Sharqawy ; Hashem, Moustafa ; Ali Abdelrahman Ghwiel</creatorcontrib><description>Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly into the tumor, minimizing systemic effects. Aim and objectives: Aim of the study was to evaluate the response of TACE treatment after 1,6,12 and 24 months comparing EASL criteria and the most recent modified RECIST (mRECIST) criteria and to assess the efficacy and tolerability of DEB-TACE for the treatment of HCC. Conclusion: DEB-TACE is more effective than cTACE in early and intermediate-stage HCC with fewer complications but without statistically significant superiority</description><identifier>EISSN: 1303-5150</identifier><identifier>DOI: 10.48047/NQ.2022.20.16.NQ88233</identifier><language>eng</language><publisher>Bornova Izmir: NeuroQuantology</publisher><subject>Cancer therapies ; Conflicts of interest ; Criteria ; Diabetes ; Epidemiology ; Hepatitis B ; Hepatitis C ; Infections ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Patients ; Radiation ; Risk factors ; Surveillance ; Testosterone ; Transplants & implants ; Tumors ; Weight control</subject><ispartof>NeuroQuantology, 2022-01, Vol.20 (16), p.2321</ispartof><rights>Copyright NeuroQuantology 2022</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Atito, Medhat A H</creatorcontrib><creatorcontrib>Mostafa Ahmed Mamdouh Al-Sharqawy</creatorcontrib><creatorcontrib>Hashem, Moustafa</creatorcontrib><creatorcontrib>Ali Abdelrahman Ghwiel</creatorcontrib><title>Endovascular Treatment of HCC</title><title>NeuroQuantology</title><description>Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly into the tumor, minimizing systemic effects. Aim and objectives: Aim of the study was to evaluate the response of TACE treatment after 1,6,12 and 24 months comparing EASL criteria and the most recent modified RECIST (mRECIST) criteria and to assess the efficacy and tolerability of DEB-TACE for the treatment of HCC. Conclusion: DEB-TACE is more effective than cTACE in early and intermediate-stage HCC with fewer complications but without statistically significant superiority</description><subject>Cancer therapies</subject><subject>Conflicts of interest</subject><subject>Criteria</subject><subject>Diabetes</subject><subject>Epidemiology</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Infections</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Patients</subject><subject>Radiation</subject><subject>Risk factors</subject><subject>Surveillance</subject><subject>Testosterone</subject><subject>Transplants & implants</subject><subject>Tumors</subject><subject>Weight control</subject><issn>1303-5150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpjYJAzNNAzsTAwMdf3C9QzMjAyAhJ6hmZ6foEWFkbGxkwMnIbGBsa6poamBhwMXMXFWQYGpuYGlmacDLKueSn5ZYnFyaU5iUUKIUWpiSW5qXklCvlpCh7OzjwMrGmJOcWpvFCam0HZzTXE2UO3oCi_sDS1uCQ-K7-0KA8oFW9kYWhmbmJkaWRkTJwqAAP0MWk</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Atito, Medhat A H</creator><creator>Mostafa Ahmed Mamdouh Al-Sharqawy</creator><creator>Hashem, Moustafa</creator><creator>Ali Abdelrahman Ghwiel</creator><general>NeuroQuantology</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20220101</creationdate><title>Endovascular Treatment of HCC</title><author>Atito, Medhat A H ; Mostafa Ahmed Mamdouh Al-Sharqawy ; Hashem, Moustafa ; Ali Abdelrahman Ghwiel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_28167429223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer therapies</topic><topic>Conflicts of interest</topic><topic>Criteria</topic><topic>Diabetes</topic><topic>Epidemiology</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Infections</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Patients</topic><topic>Radiation</topic><topic>Risk factors</topic><topic>Surveillance</topic><topic>Testosterone</topic><topic>Transplants & implants</topic><topic>Tumors</topic><topic>Weight control</topic><toplevel>online_resources</toplevel><creatorcontrib>Atito, Medhat A H</creatorcontrib><creatorcontrib>Mostafa Ahmed Mamdouh Al-Sharqawy</creatorcontrib><creatorcontrib>Hashem, Moustafa</creatorcontrib><creatorcontrib>Ali Abdelrahman Ghwiel</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>NeuroQuantology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atito, Medhat A H</au><au>Mostafa Ahmed Mamdouh Al-Sharqawy</au><au>Hashem, Moustafa</au><au>Ali Abdelrahman Ghwiel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endovascular Treatment of HCC</atitle><jtitle>NeuroQuantology</jtitle><date>2022-01-01</date><risdate>2022</risdate><volume>20</volume><issue>16</issue><spage>2321</spage><pages>2321-</pages><eissn>1303-5150</eissn><abstract>Background:Hepatic tumors, in particular hepatocellular carcinoma (HCC), present an almost exclusive arterial supply as opposed to the normal parenchyma, which is vascularized by the portal vein. The neo-angiogenesis creates the possibility of releasing high quantities of drugs or radiation directly into the tumor, minimizing systemic effects. Aim and objectives: Aim of the study was to evaluate the response of TACE treatment after 1,6,12 and 24 months comparing EASL criteria and the most recent modified RECIST (mRECIST) criteria and to assess the efficacy and tolerability of DEB-TACE for the treatment of HCC. Conclusion: DEB-TACE is more effective than cTACE in early and intermediate-stage HCC with fewer complications but without statistically significant superiority</abstract><cop>Bornova Izmir</cop><pub>NeuroQuantology</pub><doi>10.48047/NQ.2022.20.16.NQ88233</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1303-5150 |
| ispartof | NeuroQuantology, 2022-01, Vol.20 (16), p.2321 |
| issn | 1303-5150 |
| language | eng |
| recordid | cdi_proquest_journals_2816742922 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Cancer therapies Conflicts of interest Criteria Diabetes Epidemiology Hepatitis B Hepatitis C Infections Liver cancer Liver cirrhosis Liver diseases Patients Radiation Risk factors Surveillance Testosterone Transplants & implants Tumors Weight control |
| title | Endovascular Treatment of HCC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A24%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endovascular%20Treatment%20of%20HCC&rft.jtitle=NeuroQuantology&rft.au=Atito,%20Medhat%20A%20H&rft.date=2022-01-01&rft.volume=20&rft.issue=16&rft.spage=2321&rft.pages=2321-&rft.eissn=1303-5150&rft_id=info:doi/10.48047/NQ.2022.20.16.NQ88233&rft_dat=%3Cproquest%3E2816742922%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2816742922&rft_id=info:pmid/&rfr_iscdi=true |